ClinicalTrials.gg
RecruitingNCT06955624OMID-NEUROUpdated May 2, 2025

Use of Omics Methods to Classify Variations of Uncertain Significance and Improve Diagnosis of Neurogenetic Diseases

An interventional study of RNA and/or DNA methylation and/or protein analysis in Neurogenetic Diseases, sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2025, registered Apr 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Central Nervous System Diseases with a site in France — 15 open to participants now, 17 under way, 1 of them phase 3. Central Nervous System Diseases · France.

Planned enrollment
21st of 34
95 · median 183
Started
2025
with 1 other
No phase
9 of 46
5 open now
Primary completion
2030-01
later than 14 of 16 live
Registered
43rd of 46
by date

Among the 46 studies in Central Nervous System Diseases with a site in France, this one is the 21st largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, reaches primary completion later than 14 of the 16 other live ones, and was the 43rd registered.

Central Nervous System Diseases

386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.

Browse Central Nervous System Diseases studies →

Open to participants now

15 of the 46 studies in Central Nervous System Diseases with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 76 Central Nervous System Diseases studies recruiting now, 34 (45%) set no upper age limit and 22 (29%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Central Nervous System Diseases with a site in France, or all of them as a file.
02

Study summary

Many neurological disorders show a strong genetic basis, from hereditary diseases caused by a single mutation in a given gene, to diseases caused by combinations of strong genetic risk factors. However, even after the sequencing of the appropriate genes, a large proportion of patients remains undiagnosed, either because there is no candidate mutation observed, or in case of identification of a candidate mutation with insufficient knowledge to consider it as pathogenic or not.

The aim of this project is to identify the cause of neurogenetic diseases in patients in situations of diagnostic wandering or dead ends by proposing the analysis of RNA and/or proteins from different tissues.

03

Conditions studied

  • Neurogenetic Diseases

Keywords

  • Neurogenetic diseases
  • Central nervous system disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For this project, the inclusion of 3 participant profiles is required:

  • 1a. Patient, major or minor, with a neurological disease affecting the central nervous system, who has already benefited from a genomic analysis (panel, exome or genome sequencing) as part of routine care, with inconclusive analysis because the result was either a variation of uncertain significance or the absence of a variant of interest (patients with inconclusive genomic results).
  • 1b. Patient with neurological disease affecting the central nervous system, of confirmed monogenic or probable oligogenic cause (positive controls).
  • A relative of a type 1a. or 1b. patient with no symptoms of the disease, after the expected age of onset of symptoms in the patient's own family (healthy relatives).

For all 3 groups:

  • Affiliation with a social security scheme
  • Agreement to take part in the study with signature of a specific form for the study.

Exclusion criteria

Exclusion Criteria:

For patients with inconclusive results: Patient with a neurological disease not suspected of a monogenic or oligogenic cause

For healthy relatives: existence of a neurological disease (other than uncomplicated migraine) or psychiatric disease (other than simple anxiety stable under treatment).

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (estimated)

Study arms

  • Other
    Controls

    * Patients with neurological disease affecting the central nervous system, of confirmed monogenic or probable oligogenic cause (positive controls * Unaffected relatives, showing no symptoms of the disease after the expected age of onset of symptoms in the family

    Genetic: RNA and/or DNA methylation and/or protein analysis

Interventions

  • GeneticRNA and/or DNA methylation and/or protein analysis

    RNA and/or DNA methylation and/or protein analysis from a blood sample or another tissue including dedifferenciation into induced pluripotent stem cells

06

What researchers measure

Primary outcomes

  1. number and proportion of patients

    number and proportion of patients in the "Patients with inconclusive results" group for whom a final diagnosis can be made at the end of this research.

    Time frame: through study completion, an average of 5 years

Secondary outcomes

  1. Inclusion

    Inclusion of at least 50 participants with successful implementation of at least two procedures (see below, list of procedures)

    Time frame: through study completion, an average of 5 years

  2. Identification of at least one candidate biomarker linked to one or more abnormalities of a gene or group of genes.

    Identification of at least one candidate biomarker linked to one or more abnormalities of a gene or group of genes.

    Time frame: through study completion, an average of 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2030, 60 months after the start.

Of 77 non-industry interventional studies with no phase under Central Nervous System Diseases, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 60 months is above that.

Counting every sponsor, half of 88 studies reached it within 38 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
May 2, 2025
StartActual
Jan 15, 2025
Primary completionEst.
Jan 15, 2030
CompletionEst.
Jan 15, 2031
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06955624
Collaborators
University Hospital, Lille, Groupe Hospitalier Pitie-Salpetriere
Responsible party
Sponsor
First posted
May 2, 2025
Start date
Jan 15, 2025
Primary completion
Jan 15, 2030 (estimated)
Completion
Jan 15, 2031 (estimated)
Last update
May 2, 2025

Study contacts

Gaël Nicolas, MD, PhD
Contact
gael.nicolas@chu-rouen.fr
0033232888747

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion